Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Zenas BioPharma, Inc. (ZBIO) Balance Sheet

As of 2026-06-30 (10-Q), Zenas BioPharma, Inc. (ZBIO) reported total assets of $701.7M, total liabilities of $454.6M and shareholders' equity of $247.1M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $196.6M. Long-term debt: $223.0M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ZBIOZenas BioPharma, Inc.Follow ZBIO — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
1.8B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
18 Nov, in 25 days
LineFY2024
Dec 24
FY2025
Dec 25
Latest
Jun 26
Trend
Cash and equivalents319.7110.6196.6
Short-term investments31.0232.6446.5
Current assets355.9351.2653.8
Total assets370.0383.6701.7
Current liabilities57.362.665.8
Long-term debt—78.6223.0
Total liabilities57.5141.5454.6
Shareholders' equity312.5242.1247.1

USD millions · SEC XBRL

Zenas BioPharma, Inc. — questions

How much cash does Zenas BioPharma, Inc. have?
$196.6M in cash and cash equivalents as of 2026-06-30.
How much debt does Zenas BioPharma, Inc. have?
$223.0M of long-term debt as of 2026-06-30.
What are Zenas BioPharma, Inc.'s total assets?
$701.7M as of 2026-06-30.
What is Zenas BioPharma, Inc.'s shareholders' equity?
$247.1M as of 2026-06-30.

Every figure on this page comes from Zenas BioPharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.